RU2397768C2 - Композиции для преодоления опосредованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенные для инъекции - Google Patents
Композиции для преодоления опосредованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенные для инъекции Download PDFInfo
- Publication number
- RU2397768C2 RU2397768C2 RU2007124325/15A RU2007124325A RU2397768C2 RU 2397768 C2 RU2397768 C2 RU 2397768C2 RU 2007124325/15 A RU2007124325/15 A RU 2007124325/15A RU 2007124325 A RU2007124325 A RU 2007124325A RU 2397768 C2 RU2397768 C2 RU 2397768C2
- Authority
- RU
- Russia
- Prior art keywords
- sodium
- sulbactam
- composition
- ceftriaxone
- beta
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 102000006635 beta-lactamase Human genes 0.000 title claims abstract description 23
- 108090000204 Dipeptidase 1 Proteins 0.000 title claims abstract description 12
- 238000002347 injection Methods 0.000 title claims abstract description 10
- 239000007924 injection Substances 0.000 title claims abstract description 10
- 230000001404 mediated effect Effects 0.000 title claims abstract description 8
- 239000003781 beta lactamase inhibitor Substances 0.000 title claims description 12
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title claims description 12
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title claims description 9
- 239000003242 anti bacterial agent Substances 0.000 title abstract description 10
- 229940088710 antibiotic agent Drugs 0.000 title abstract description 7
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 229960004755 ceftriaxone Drugs 0.000 claims abstract description 30
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 29
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims abstract description 29
- 229960005256 sulbactam Drugs 0.000 claims abstract description 28
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 27
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 27
- 239000011734 sodium Substances 0.000 claims abstract description 27
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims abstract description 27
- 239000000243 solution Substances 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims abstract description 8
- 239000007787 solid Substances 0.000 claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 7
- 229960000479 ceftriaxone sodium Drugs 0.000 claims description 33
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 claims description 33
- 239000002253 acid Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 230000003115 biocidal effect Effects 0.000 claims description 12
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 10
- 239000011261 inert gas Substances 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 10
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 238000007911 parenteral administration Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 159000000000 sodium salts Chemical class 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 4
- 229960003324 clavulanic acid Drugs 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 239000008228 bacteriostatic water for injection Substances 0.000 claims description 3
- 229910052756 noble gas Inorganic materials 0.000 claims description 3
- 150000002835 noble gases Chemical class 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960004261 cefotaxime Drugs 0.000 claims description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims description 2
- 229960000484 ceftazidime Drugs 0.000 claims description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 229960002100 cefepime Drugs 0.000 claims 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims 1
- 229960000466 cefpirome Drugs 0.000 claims 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 claims 1
- 229960001668 cefuroxime Drugs 0.000 claims 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims 1
- 229960003865 tazobactam Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 238000007918 intramuscular administration Methods 0.000 abstract description 5
- 238000001990 intravenous administration Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 108020004256 Beta-lactamase Proteins 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 5
- -1 oxyimino Chemical group 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229960000614 sulbactam sodium Drugs 0.000 description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
- 206010034133 Pathogen resistance Diseases 0.000 description 4
- 229960001484 edetic acid Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229960003330 pentetic acid Drugs 0.000 description 4
- 150000003952 β-lactams Chemical class 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940043312 ampicillin / sulbactam Drugs 0.000 description 3
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 3
- 229960004659 ticarcillin Drugs 0.000 description 3
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 2
- AURFNYPOUVLIAV-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]-2-hydroxyacetic acid Chemical compound OC(=O)C(O)N(CC(O)=O)CCN(CC(O)=O)CC(O)=O AURFNYPOUVLIAV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- 238000002960 beta lactamase induction Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 2
- 238000012859 sterile filling Methods 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- SCNWTQPZTZMXBG-UHFFFAOYSA-N 2-methyloct-2-enoic acid Chemical compound CCCCCC=C(C)C(O)=O SCNWTQPZTZMXBG-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- 229940123930 Lactamase inhibitor Drugs 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 125000001550 cephem group Chemical group 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009112 empiric therapy Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical class OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2411/DEL/2004 | 2004-12-02 | ||
| IN2411DE2004 | 2004-12-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007124325A RU2007124325A (ru) | 2009-01-10 |
| RU2397768C2 true RU2397768C2 (ru) | 2010-08-27 |
Family
ID=35789266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007124325/15A RU2397768C2 (ru) | 2004-12-02 | 2005-11-28 | Композиции для преодоления опосредованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенные для инъекции |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8273732B2 (enExample) |
| EP (1) | EP1841432B1 (enExample) |
| JP (1) | JP5269415B2 (enExample) |
| KR (2) | KR20070067189A (enExample) |
| CN (1) | CN101060846A (enExample) |
| AT (1) | ATE476981T1 (enExample) |
| AU (1) | AU2005310888B2 (enExample) |
| BR (1) | BRPI0517128A (enExample) |
| CY (1) | CY1110886T1 (enExample) |
| DE (1) | DE602005022939D1 (enExample) |
| DK (1) | DK1841432T3 (enExample) |
| ES (1) | ES2349301T3 (enExample) |
| HR (1) | HRP20100591T1 (enExample) |
| MX (1) | MX2007006540A (enExample) |
| NZ (1) | NZ555075A (enExample) |
| PL (1) | PL1841432T3 (enExample) |
| PT (1) | PT1841432E (enExample) |
| RS (1) | RS51506B (enExample) |
| RU (1) | RU2397768C2 (enExample) |
| SI (1) | SI1841432T1 (enExample) |
| UA (1) | UA91204C2 (enExample) |
| WO (1) | WO2006059344A1 (enExample) |
| ZA (1) | ZA200704394B (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014052799A1 (en) * | 2012-09-27 | 2014-04-03 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine antibiotic compositions |
| RU2569059C2 (ru) * | 2011-07-26 | 2015-11-20 | Вокхардт Лимитед | Фармацевтические композиции, содержащие бета-лактамный антибиотик, сульбактам и ингибитор бета-лактамаз |
| RU2593363C2 (ru) * | 2011-05-28 | 2016-08-10 | Вокхардт Лимитед | Композиции, включающие антибактериальное средство и тазобактам |
| RU2671971C2 (ru) * | 2014-04-03 | 2018-11-08 | Бакстер Интернэшнл Инкорпорейтед | Пакет для инъекционного раствора и сборная конструкция с препаратом инъекционного раствора |
| RU2825961C1 (ru) * | 2023-08-30 | 2024-09-02 | Станислав Михайлович Сидоров | Фармацевтическая композиция для лечения бактериальных инфекций, вызванных основными возбудителями патогенов |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030010176A (ko) * | 2001-07-25 | 2003-02-05 | 이병두 | 은행 열매 추출물과 호도 열매 추출물을 이용한 천식 치료제 |
| CN101129381B (zh) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| JP5639471B2 (ja) * | 2008-07-28 | 2014-12-10 | 惠三 山口 | 感染症治療効果増強剤 |
| CN101537009B (zh) * | 2009-04-30 | 2010-09-15 | 海口奇力制药股份有限公司 | 注射用头孢曲松钠他唑巴坦钠复方制剂的生产工艺 |
| JP2012176899A (ja) * | 2009-05-19 | 2012-09-13 | Mitsubishi Tanabe Pharma Corp | ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液 |
| WO2013042140A2 (en) * | 2011-09-23 | 2013-03-28 | Manu Chaudhary | Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement |
| MY169816A (en) | 2012-03-26 | 2019-05-16 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol |
| EP2858636B1 (en) | 2012-06-07 | 2018-09-05 | Childrens Hospital Los Angeles | Methods for treating neutropenia using retinoid agonists |
| MX2016010699A (es) | 2014-02-18 | 2017-10-11 | Children's Hospital Los Angeles | Composiciones y metodos para tratar neutropenia. |
| EP3125887A1 (en) * | 2014-03-29 | 2017-02-08 | Wockhardt Limited | Pharmaceutical compositions comprising cefepime or sulbactam |
| US10201518B2 (en) | 2016-09-28 | 2019-02-12 | The University Of Hong Kong | Bismuth(III) compounds and methods thereof |
| JP6891275B2 (ja) * | 2016-11-02 | 2021-06-18 | 湘北威爾曼制薬股▲分▼有限公司Ｘｉａｎｇｂｅｉ Ｗｅｌｍａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ | セフトリアキソンナトリウムとスルバクタムナトリウムからなる組成物 |
| CN111249284B (zh) * | 2016-11-03 | 2022-10-04 | 湘北威尔曼制药股份有限公司 | 治疗淋病奈瑟菌感染的头孢曲松钠舒巴坦钠 |
| RU2665006C1 (ru) * | 2017-02-28 | 2018-08-24 | Общество с ограниченной ответственностью "Супербаг Солюшенс" | Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения |
| EP4272831A3 (en) | 2018-08-09 | 2024-02-21 | Antabio SAS | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| EP4262860A4 (en) | 2020-12-17 | 2025-11-12 | Idexx Lab Inc | DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER |
| WO2025165991A1 (en) * | 2024-01-31 | 2025-08-07 | The Penn State Research Foundation | Biopolymeric anti-antibiotics and methods for making and using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630510B1 (en) * | 1999-10-28 | 2003-10-07 | Merck & Co., Inc. | Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections |
| US6677320B2 (en) * | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
| PL1468697T3 (pl) * | 2003-04-14 | 2008-05-30 | Wyeth Corp | Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań |
-
2005
- 2005-11-28 RS RSP-2010/0465A patent/RS51506B/sr unknown
- 2005-11-28 CN CNA2005800395645A patent/CN101060846A/zh active Pending
- 2005-11-28 MX MX2007006540A patent/MX2007006540A/es active IP Right Grant
- 2005-11-28 US US11/720,710 patent/US8273732B2/en not_active Expired - Fee Related
- 2005-11-28 AU AU2005310888A patent/AU2005310888B2/en not_active Ceased
- 2005-11-28 UA UAA200707280A patent/UA91204C2/ru unknown
- 2005-11-28 WO PCT/IN2005/000382 patent/WO2006059344A1/en not_active Ceased
- 2005-11-28 PL PL05817957T patent/PL1841432T3/pl unknown
- 2005-11-28 JP JP2007544016A patent/JP5269415B2/ja not_active Expired - Fee Related
- 2005-11-28 KR KR1020077010375A patent/KR20070067189A/ko not_active Ceased
- 2005-11-28 SI SI200531130T patent/SI1841432T1/sl unknown
- 2005-11-28 DE DE602005022939T patent/DE602005022939D1/de not_active Expired - Lifetime
- 2005-11-28 BR BRPI0517128-8A patent/BRPI0517128A/pt not_active IP Right Cessation
- 2005-11-28 EP EP05817957A patent/EP1841432B1/en not_active Expired - Lifetime
- 2005-11-28 KR KR1020097018388A patent/KR101244362B1/ko not_active Expired - Fee Related
- 2005-11-28 ES ES05817957T patent/ES2349301T3/es not_active Expired - Lifetime
- 2005-11-28 RU RU2007124325/15A patent/RU2397768C2/ru not_active IP Right Cessation
- 2005-11-28 HR HR20100591T patent/HRP20100591T1/hr unknown
- 2005-11-28 DK DK05817957.3T patent/DK1841432T3/da active
- 2005-11-28 PT PT05817957T patent/PT1841432E/pt unknown
- 2005-11-28 NZ NZ555075A patent/NZ555075A/en not_active IP Right Cessation
- 2005-11-28 AT AT05817957T patent/ATE476981T1/de active
-
2007
- 2007-05-29 ZA ZA200704394A patent/ZA200704394B/xx unknown
-
2010
- 2010-11-10 CY CY20101101012T patent/CY1110886T1/el unknown
-
2012
- 2012-09-25 US US13/626,236 patent/US9012442B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| Fantin В., et al., Activity of Sulbactam in Combination with Ceftriaxone In Vitro and in Experimental Endocarditis Caused by Escherichia coli Producing SHV-2-Like r-Lactamase, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, v.34, № 4, p.581-586. G.A.PANKUCH, et al., Susceptibilities of 200 Penicillin-Susceptible and - Resistant Pneumococci to Piperacillin, Piperacillin-Tazobactam, Ticarcillin, Ticarcillin-Clavulanate, Ampicillin, Ampicillin-Sulbactam, Ceftazidime, and Ceftriaxone, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, v.38, № 12, p.2905-2907. Под ред. проф. В.И.Чуешова, Промышленная технология лекарств. - Харьков: Издательство НФАУ, МТК-Книга, 2002, т.2, с.526. Федоренко В.И. Ингибирование осадкообразования в установках обратного осмоса. Серия Критические технологии, 2003, №2(18), с.23-30. * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2593363C2 (ru) * | 2011-05-28 | 2016-08-10 | Вокхардт Лимитед | Композиции, включающие антибактериальное средство и тазобактам |
| RU2569059C2 (ru) * | 2011-07-26 | 2015-11-20 | Вокхардт Лимитед | Фармацевтические композиции, содержащие бета-лактамный антибиотик, сульбактам и ингибитор бета-лактамаз |
| WO2014052799A1 (en) * | 2012-09-27 | 2014-04-03 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine antibiotic compositions |
| RU2671485C2 (ru) * | 2012-09-27 | 2018-11-01 | Мерк Шарп И Доум Корп. | Антибиотические композиции тазобактама аргинина |
| RU2671971C2 (ru) * | 2014-04-03 | 2018-11-08 | Бакстер Интернэшнл Инкорпорейтед | Пакет для инъекционного раствора и сборная конструкция с препаратом инъекционного раствора |
| RU2825961C1 (ru) * | 2023-08-30 | 2024-09-02 | Станислав Михайлович Сидоров | Фармацевтическая композиция для лечения бактериальных инфекций, вызванных основными возбудителями патогенов |
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005022939D1 (de) | 2010-09-23 |
| RU2007124325A (ru) | 2009-01-10 |
| WO2006059344A1 (en) | 2006-06-08 |
| KR20090101514A (ko) | 2009-09-28 |
| ZA200704394B (en) | 2008-09-25 |
| US8273732B2 (en) | 2012-09-25 |
| PT1841432E (pt) | 2010-10-25 |
| JP2008521884A (ja) | 2008-06-26 |
| HRP20100591T1 (hr) | 2010-12-31 |
| SI1841432T1 (sl) | 2011-02-28 |
| WO2006059344B1 (en) | 2006-11-02 |
| EP1841432A1 (en) | 2007-10-10 |
| KR20070067189A (ko) | 2007-06-27 |
| CN101060846A (zh) | 2007-10-24 |
| US9012442B2 (en) | 2015-04-21 |
| DK1841432T3 (da) | 2010-12-06 |
| BRPI0517128A (pt) | 2008-09-30 |
| ES2349301T3 (es) | 2010-12-29 |
| EP1841432B1 (en) | 2010-08-11 |
| US20100160277A1 (en) | 2010-06-24 |
| PL1841432T3 (pl) | 2011-01-31 |
| KR101244362B1 (ko) | 2013-03-18 |
| JP5269415B2 (ja) | 2013-08-21 |
| NZ555075A (en) | 2011-02-25 |
| UA91204C2 (ru) | 2010-07-12 |
| US20130023512A1 (en) | 2013-01-24 |
| AU2005310888A1 (en) | 2006-06-08 |
| RS51506B (sr) | 2011-06-30 |
| CY1110886T1 (el) | 2015-06-10 |
| ATE476981T1 (de) | 2010-08-15 |
| AU2005310888B2 (en) | 2011-01-06 |
| MX2007006540A (es) | 2008-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9012442B2 (en) | Compositions for combating beta-lactamase-medicated antibiotic resistance using beta-lactamase inhibitors useful for injection | |
| CN103648496B (zh) | 包含β-内酰胺抗生素、舒巴坦和β-内酰胺酶抑制剂的药物组合物 | |
| AU2017339587A1 (en) | Combination therapy with amidine substituted ß-lactam compounds and ß-lactamase inhibitors for infections with antibiotic resistant bacterial strains | |
| EP2066302A2 (en) | Stabilizing compositions for antibiotics and methods of use | |
| CN102292079B (zh) | 包含头孢洛林的组合物和治疗方法 | |
| CN113194943B (zh) | 一种具有稳定性和抑菌活性的含有头孢噻肟舒巴坦或头孢噻肟他唑巴坦的药物组合物 | |
| CA2591157C (en) | Antibiotic combinations for providing total solution to the treatment of infections | |
| EP4694888A1 (en) | Pharmaceutical combinations and compositions thereof comprising antibacterial agents | |
| EP1604660B1 (en) | Medicinal composition for treating infection with drug-resistant staphylococcus aureus | |
| RU2424801C1 (ru) | Средство для лечения инфекционных болезней | |
| CN1582942A (zh) | 头孢呋辛钠复方制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20161129 |